Skip to main content
RELMADA THERAPEUTICS, INC. logo

RELMADA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · RLMD ISIN · US75954H1005 LEI · 549300217EASRZ9JSF81 US Professional, scientific and technical activities
Open in API
Filings indexed 582 across all filing types
Latest filing 2015-08-10 Share Issue/Capital Cha…
Country US United States of America
Listing US RLMD

About RELMADA THERAPEUTICS, INC.

https://www.relmada.com/

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapies. The company's lead program is NDV-01, a sustained-release, intravesical formulation of gemcitabine and docetaxel for the treatment of non-muscle invasive bladder cancer. The formulation is designed for gradual drug release over 10 days to enhance local exposure and minimize systemic toxicity. Relmada's pipeline also includes Sepranolone, which is being developed for compulsive disorders. Following positive proof-of-concept data in Tourette’s syndrome, the company is planning a Phase 2 study of Sepranolone in Prader-Willi Syndrome, a rare genetic disorder.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Share Issue/Capital Change Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 4, 2015, by Relmada Therapeutics, Inc. The content focuses on the announcement of a reverse stock split (1-for-5) approved by the Board of Directors, including details about the effective date, stock symbol changes, treatment of fractional shares, and related corporate actions. There are no financial statements or detailed financial performance data included. The document is primarily an announcement of a capital structure change (reverse stock split) and related corporate governance actions. This fits the category of a Share Issue/Capital Change (SHA) filing, as it announces a change in the company's capital structure through a reverse stock split. The document length (10,775 characters) and detailed explanation support this classification with high confidence.
2015-08-10 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 3, 2015, by Relmada Therapeutics, Inc. It details several corporate events including amendments to stock option plans, indemnification agreements, amendments to bylaws, termination of a material definitive agreement, and employment agreements for officers. The content focuses on corporate governance changes, employment agreements, and material contracts rather than financial results or earnings. There are no financial statements or earnings data presented, nor is this a proxy or voting results announcement. The document is a regulatory filing reporting material corporate events as required by the SEC under the Securities Exchange Act of 1934. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories.
2015-08-07 English
OWNERSHIP DOCUMENT
Director's Dealing
2015-07-16 English
CURRENT REPORT
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 14, 2015. The content focuses on the appointment of a new director, Charles J. Casamento, to the board of directors, including details about his background, committee appointments, compensation, and related agreements. There is no financial data or earnings information presented. The primary subject is changes in the company's board of directors and senior management. According to the filing definitions, announcements of changes in the company's board or senior management fall under Board/Management Information (MANG). The document length is 9273 characters, which is substantive and contains detailed information about the management change, not just a brief announcement or press release. Therefore, the appropriate classification is MANG with high confidence.
2015-07-16 English
CURRENT REPORT
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, which is used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a lease agreement for new corporate headquarters. There are no financial statements or quarterly/annual financial results presented, nor is this a report of earnings, management discussion, or audit. The document is not an announcement of voting results, nor a proxy solicitation, nor a merger/acquisition filing. It is a regulatory filing to disclose a material event (lease agreement) as required by the Securities Exchange Act of 1934. The document length is under 5,000 characters and contains the full text of the announcement, not just a notice of report publication. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-06-13 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 22, 2015. It includes a corporate presentation as an exhibit and states that the information is "furnished" and not "filed" under the Securities Exchange Act. The document is short (2988 characters) and primarily serves to disclose the furnishing of a corporate presentation rather than containing detailed financial data or comprehensive report content. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain substantive financial statements or detailed report content itself.
2015-05-22 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.